{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:38:20Z","timestamp":1773722300756,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022957","name":"Double Thousand Plan of Jiangxi Province","doi-asserted-by":"publisher","award":["jxsq2020101090"],"award-info":[{"award-number":["jxsq2020101090"]}],"id":[{"id":"10.13039\/100022957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BAB206094"],"award-info":[{"award-number":["20212BAB206094"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008534","name":"Northeast Agricultural University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijbiomac.2024.129797","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T02:24:03Z","timestamp":1706495043000},"page":"129797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis"],"prefix":"10.1016","volume":"261","author":[{"given":"Jianying","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YunZhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianlong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2024.129797_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"Qjm-Int. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0010","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cmet.2018.10.012","article-title":"Preclinical models for studying NASH-driven HCC: how useful are they?","volume":"29","author":"Febbraio","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0025","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1208\/s12248-010-9218-9","article-title":"Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor","volume":"12","author":"Hall","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0045","article-title":"Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese","volume":"6","author":"Lin","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.28523","article-title":"Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice","volume":"64","author":"Gong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0055","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/db20-0209","article-title":"The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman primates","volume":"69","author":"Cui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0060","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0065","first-page":"1242","article-title":"Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet","volume":"2015","author":"Tanaka","year":"1852","journal-title":"BBA-Mol. Basis Dis."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0070","first-page":"E1105","article-title":"Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects","volume":"297","author":"Xu","year":"2009","journal-title":"Am. J. Physiol-Endoc. M."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0075","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jconrel.2020.05.036","article-title":"Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects","volume":"324","author":"Watanabe","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0085","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2023.01.039","article-title":"Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease","volume":"355","author":"Chikamatsu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0095","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2174\/1389201015666140515124838","article-title":"Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation","volume":"14","author":"Ye","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0100","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijbiomac.2019.05.167","article-title":"An efficient large-scale refolding technique for recovering biologically active recombinant human FGF-21 from inclusion bodies","volume":"135","author":"Ye","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.febslet.2008.11.023","article-title":"FGF21 N- and C-termini play different roles in receptor interaction and activation","volume":"583","author":"Yie","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0110","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0115","first-page":"2133","article-title":"PEGylation and its impact on the design of new protein-based medicines (vol 6, pg 1829, 2014)","volume":"6","author":"Ginn","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0120","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/bit.21482","article-title":"Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules","volume":"98","author":"Fee","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0125","first-page":"594","article-title":"Size of pegylated protein conjugates studied by various methods","volume":"55","author":"Kusterle","year":"2008","journal-title":"Acta Chim. Slov."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0130","doi-asserted-by":"crossref","first-page":"13196","DOI":"10.1021\/bi00040a035","article-title":"N-terminus and lysine side chain pKa values of melittin in aqueous solutions and micellar dispersions measured by 15N NMR","volume":"34","author":"Zhu","year":"1995","journal-title":"Biochemistry (Mosc.)"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0135","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0169-409X(02)00023-6","article-title":"Colin Gegg, mono-N-terminal poly(ethylene glycol)\u2013protein conjugates","volume":"54","author":"Olaf Kinstler","year":"2002","journal-title":"Adv. Drug. Deliver. Rev."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0140","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1023\/A:1016042220817","article-title":"Characterization and stability of N-terminally PEGylated rhG-CSF","volume":"13","author":"Kinstler","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0145","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nbt812","article-title":"Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity","volume":"21","author":"Yoko Yamamoto","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0150","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2014.02.002","article-title":"Process for protein PEGylation","volume":"180","author":"Pfister","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0155","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward beta-klotho, and enhanced efficacy in mice and cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-6750-10-14","article-title":"High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli","volume":"10","author":"Wang","year":"2010","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00253-011-3427-8","article-title":"Large-scale expression, purification, and glucose uptake activity of recombinant human FGF21 in Escherichia coli","volume":"93","author":"Zhang","year":"2012","journal-title":"Appl. Microbiol. Biot."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jbiotec.2016.04.038","article-title":"Pilot-scale production and characterization of PEGylated human FGF-21 analog","volume":"228","author":"Ye","year":"2016","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0175","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2009.02.010","article-title":"PEG conjugates in clinical development or use as anticancer agents: an overview","volume":"61","author":"Pasut","year":"2009","journal-title":"Adv. Drug. Deliver. Rev."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Francesco","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0185","article-title":"A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol","volume":"6","author":"Huang","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jevsevar","year":"2010","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0195","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.4155\/fmc.14.125","article-title":"PEGylation and its impact on the design of new protein-based medicines","volume":"6","author":"Ginn","year":"2014","journal-title":"Futur. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0200","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","article-title":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","volume":"22","author":"Hansen","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0205","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab."},{"key":"10.1016\/j.ijbiomac.2024.129797_bb0215","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024006007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024006007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:21:32Z","timestamp":1758885692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024006007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":43,"alternative-id":["S0141813024006007"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129797","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129797"}}